NicOx and Bausch + Lomb have announced that they have entered into a licensing agreement which grants Bausch + Lomb exclusive worldwide rights to develop and commercialise NCX 116, a nitric oxide‑donating prostaglandin F2a-analog.
NCX 116 has already completed two phase 2 studies in patients with glaucoma andocular hypertension, which demonstrated promising results.
Glaucoma is one of a group of eye diseases which can lead to the loss of peripheral vision and eventually total blindness, and the companies are keen to find a means of treatment for patients worldwide.
Dr Baldo Scassellati Sforzolini, Vice President Regulatory Affairs, Clinical & Medical Sciences at Bausch + Lomb, commented: “We look forward to this promising collaboration with NicOx, which further strengthens Bausch + Lomb’s product pipeline and potentially enables the company to provide patients with a worldwide prescription product for the treatment of glaucoma.”
Gavin Spencer, Vice President Business Development at NicOx, commented: “As one of the best-known and most respected healthcare companies in the world, dedicated specifically to eye health, Bausch + Lomb recognises the potential of NCX 116. We believe that their therapeutic focus offers a great opportunity to develop this molecule in glaucoma and we look forward to a strong collaboration.”
NicOx has granted Bausch + Lomb the exclusive worldwide rights to develop and commercialize NCX 116 and other products containing NCX 116, such as fixed-dose combinations, for the treatment of glaucoma and ocular hypertension.
Bausch + Lomb has the option to develop additional nitric oxide-donating compounds for the treatment of glaucoma and ocular hypertension, including the other prostaglandin F2a-analogs resulting from NicOx’s research.
To find out more, click the link below: